Ross A. Soo

19.4k total citations · 6 hit papers
308 papers, 9.6k citations indexed

About

Ross A. Soo is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ross A. Soo has authored 308 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 220 papers in Pulmonary and Respiratory Medicine, 213 papers in Oncology and 71 papers in Molecular Biology. Recurrent topics in Ross A. Soo's work include Lung Cancer Treatments and Mutations (201 papers), Lung Cancer Research Studies (72 papers) and Colorectal Cancer Treatments and Studies (67 papers). Ross A. Soo is often cited by papers focused on Lung Cancer Treatments and Mutations (201 papers), Lung Cancer Research Studies (72 papers) and Colorectal Cancer Treatments and Studies (67 papers). Ross A. Soo collaborates with scholars based in Singapore, United States and South Korea. Ross A. Soo's co-authors include Byoung Chul Cho, Nicholas Syn, Tony Mok, Richie Soong, Michele W.L. Teng, Sai‐Hong Ignatius Ou, Daniel Shao-Weng Tan, Sun Min Lim, Wan‐Teck Lim and Jongyoon Han and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Cancer Cell.

In The Last Decade

Ross A. Soo

290 papers receiving 9.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Isolation and retrieval of circulating tumor cells using centrifugal forces

2013 595 citations Ross A. Soo, Wan‐Teck Lim et al. profile →
De-novo and acquired resistance to immune checkpoint targeting

2017 555 citations Nicholas Syn, Tony Mok et al. profile →
Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial

2020 405 citations Ross A. Soo et al. Journal of Thoracic Oncology profile →
ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

2019 269 citations Alice T. Shaw, Benjamin Solomon et al. Journal of Clinical Oncology profile →
Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study

2022 129 citations Benjamin Solomon, Todd M. Bauer et al. profile →
Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study

2024 118 citations Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ross A. Soo

Since Specialization

Citations

This map shows the geographic impact of Ross A. Soo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross A. Soo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross A. Soo more than expected).

Fields of papers citing papers by Ross A. Soo

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ross A. Soo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross A. Soo. The network helps show where Ross A. Soo may publish in the future.

Co-authorship network of co-authors of Ross A. Soo

This figure shows the co-authorship network connecting the top 25 collaborators of Ross A. Soo. A scholar is included among the top collaborators of Ross A. Soo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ross A. Soo. Ross A. Soo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Modulating the gut microbiome in non-small cell lung cancer: Challenges and opportunities 2024 ·Lung Cancer ·Jii Bum Lee, Yiqing Huang, Yuko Oya, (unknown), (unknown), (unknown), Byoung Chul Cho, Ross A. Soo	3
2	ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial 2024 ·Clinical Cancer Research ·Ross A. Soo, Urania Dafni, Ji‐Youn Han, Byoung Chul Cho, Ernest Nadal, (unknown), Enric Carcereny, Javier de Castro, (unknown), Linda Coate, Mariano Provencio, Christian Britschgi, (unknown), (unknown), Roswitha Kammler, Stephen P. Finn, Solange Peters, Rolf A. Stahel, (unknown)	1
3	Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations. 2024 ·Journal of Clinical Oncology ·Melissa L. Johnson, Ross A. Soo, Yi‐Long Wu, (unknown), (unknown), (unknown), Tatsuya Yoshida	2
4	Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study breakdown → 2024 ·Journal of Clinical Oncology ·Benjamin Solomon, Geoffrey Liu, Enriqueta Felip, Tony Mok, Ross A. Soo, Julien Mazières, Alice T. Shaw, Filippo de Marinis, Yasushi Goto, Yi‐Long Wu, Dong‐Wan Kim, Jean-François Martini, Rossella Messina, Jolanda Paolini, Anna Polli, Despina Thomaidou, Francesca Toffalorio, Todd M. Bauer	118
5	Abstract CT284: A phase 3 randomized controlled trial of zongertinib (BI 1810631) compared with standard of care in patients with locally advanced or metastatic nonsquamous non-small cell lung cancer harboring HER2 tyrosine kinase domain mutations: Beamion LUNG-2 2024 ·Cancer Research ·Yi‐Long Wu, Melissa L. Johnson, Ross A. Soo, (unknown), (unknown), (unknown), Tatsuya Yoshida	0
6	Factors Predictive of Primary Resistance to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer 2023 ·Cancers ·Yiqing Huang, Joseph J. Zhao, Yu Yang Soon, Adrian Kee, Sen Hee Tay, Folefac Aminkeng, Yvonne Ang, Alvin Wong, Lavina Bharwani, Boon Cher Goh, Ross A. Soo	12
7	Molecular testing in non-small cell lung cancer: A consensus recommendation 2023 ·Annals of the Academy of Medicine Singapore ·Gillianne Lai, Xin Cheng, Yvonne Ang, Kevin Lee Min Chua, Jens Samol, Ross A. Soo, Daniel S.W. Tan, Tony Kiat Hon Lim, Wan‐Teck Lim	0
8	EP06.03-10 HER3 Expression in Archived Tissue Samples from Patients with NSCLC Across Various Genomic Subtypes and Characteristics 2023 ·Journal of Thoracic Oncology ·Ross A. Soo, A. Srikantha Phani, Christina Wu, (unknown), (unknown), Parita Patel, Lukas Bubendorf	1
9	Randomized Trial of Tepotinib Plus Gefitinib versus Chemotherapy in EGFR -Mutant NSCLC with EGFR Inhibitor Resistance Due to MET Amplification: INSIGHT Final Analysis 2023 ·Clinical Cancer Research ·Chong Kin Liam, (unknown), Te‐Chun Hsia, Jianying Zhou, Dong‐Wan Kim, Ross A. Soo, Ying Cheng, Shun Lü, Sang Won Shin, James Chih‐Hsin Yang, (unknown), Jun Zhao, Karin Berghoff, Rolf Bruns, Andreas Johne, Yi‐Long Wu	22
10	Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations 2023 ·Therapeutic Advances in Medical Oncology ·(unknown), Sun Min Lim, Jii Bum Lee, Byoung Chul Cho, Ross A. Soo	13
11	Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC 2023 ·Journal of Thoracic Oncology ·Ross A. Soo, Jean‐François Martini, Anthonie J. van der Wekken, Shunsuke Teraoka, Roberto Ferrara, Alice T. Shaw, (unknown), Anna Maria Calella, Anna Polli, Francesca Toffalorio, Pascale Tomasini, Chao‐Hua Chiu, Dariusz M. Kowalski, Hye Ryun Kim, Benjamin Solomon	22
12	Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer 2022 ·Therapeutic Advances in Medical Oncology ·Jiyun Lee, Zofia Piotrowska, Ross A. Soo, Byoung Chul Cho, Sun Min Lim	8
13	Phase I results of S49076 plus gefitinib in patients with EGFR TKI-resistant non-small cell lung cancer harbouring MET/AXL dysregulation 2021 ·Lung Cancer ·Keunchil Park, Gee‐Chen Chang, Giuseppe Curigliano, Wan‐Teck Lim, Ross A. Soo, Miguel Ángel Molina‐Vila, Valérie Cattan, (unknown), (unknown), (unknown), (unknown), Santiago Viteri	10
14	Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK ‐rearranged lung cancer 2019 ·EMBO Molecular Medicine ·Mi Ran Yun, (unknown), You Won Lee, (unknown), Chae Won Park, Jae Woo Choi, (unknown), Han Na Kang, Kyoung‐Ho Pyo, Eun Joo Shin, Hyo Sup Shim, Ross A. Soo, James Chih‐Hsin Yang, Sung Sook Lee, Hyun Chang, Min Hwan Kim, Min Hee Hong, Hye Ryun Kim, Byoung Chul Cho	46
15	Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study 2017 ·International Journal of Cancer ·Valerie Heong, Nicholas Syn, (unknown), Nur Sabrina Sapari, (unknown), (unknown), (unknown), Diana Lim, Brendan Pang, Yee Liang Thian, (unknown), Andrea Li‐Ann Wong, Ross A. Soo, Wei Peng Yong, Cheng Ean Chee, Soo Chin Lee, Boon Cher Goh, Richie Soong, David S.P. Tan	9
16	MEK Inhibition Overcomes Cisplatin Resistance Conferred by SOS/MAPK Pathway Activation in Squamous Cell Carcinoma 2015 ·Molecular Cancer Therapeutics ·Li Ren Kong, Kian Ngiap Chua, Wen Jing Sim, (unknown), Chonglei Bi, Jingshan Ho, Min En Nga, Yin Huei Pang, (unknown), Ross A. Soo, Hung Huynh, Wee Joo Chng, Jean Paul Thiery, Boon Cher Goh	41
17	β-Catenin Contributes to Lung Tumor Development Induced by EGFR Mutations 2014 ·Cancer Research ·Sohei Nakayama, Natasha Sng, Julián Carretero, Robert S. Welner, Yuichiro Hayashi, Mihoko Yamamoto, (unknown), Norihiro Yamaguchi, Hiroyuki Yasuda, Danan Li, Kenzo Soejima, Ross A. Soo, Daniel B. Costa, Kwok‐Kin Wong, Susumu Kobayashi	72
18	Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation 2012 ·Molecular Cancer Therapeutics ·Sun Mi Kim, Oh-Joon Kwon, Yun Hong, Joo Hang Kim, Flavio Solca, Sang‐Jun Ha, Ross A. Soo, James G. Christensen, Ji Hyun Lee, Byoung Chul Cho	172
19	Upregulation of plasma C9 protein in gastric cancer patients 2010 ·PROTEOMICS - CLINICAL APPLICATIONS ·(unknown), Huiyin Lee, (unknown), (unknown), Qingsong Lin, Jimmy Bok Yan So, (unknown), Ross A. Soo, Wei Peng Yong, Siew Pang Chan, Duane T. Smoot, Hassan Ashktorab, Khay Guan Yeoh, Yoon Lim	2
20	Pharmacodynamic effects of seliciclib (R-roscovitine, CYC202) in patients with undifferentiated nasopharyngeal carcinoma (NPC) using a window trial design. 2005 ·Clinical Cancer Research ·Wen-Son Hsieh, (unknown), (unknown), Judy H. Chiao, Ross A. Soo, (unknown), (unknown), (unknown), Manuel Salto‐Tellez, Benjamin Mow, Brian C. Goh	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact